Genmab — Januar 2020

[Helge_LarsenPI-redaktør]

God morgen.

[StockBull]

Den er er også meget sjov og man ser tydligt CWH er intakt https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/81009_sjov.JPG

[Jørn_B]

@Stockbull. Tak... Lad os bare holde os til den sidste, så er jeg ikke utilfreds

[Bulder]

Ritzau skriver at Cassiopeia er godkendt i Japan. Det passer vist ikke. Jeg har ikke kunnet finde noget på Japan. I USA derimod er Cass godkendt. Til gengæld kan vi snart forvente godkendelse af Maia i Japan. Ansøgning 5. april.

[Bulder]

... sidste år, og da Alcyone tog 9-10 mdr i Japan, må det være lige oppe over.

[Bulder]

Har de overhovedet søgt på Cassiopeia i Japan? Jeg kan ikke finde noget. Andre?

[Darvin]

Kkjoel 15.32 and EL 15.51 - my estimates, based on exactly the same growth figures in the US as in 2019 and a sharp reduction in growth ROW will be 4.3 with upside to 4.4. I am lowering ROW growth to one third of growth in 2019. It should be said that SC can mean higher growth rates in 20 than in 19, but I did not take that into consideration, but instead use it to maintain the growth rate of 2019. If SC give an increased growth rate, we should probably go higher.

[Darvin]

And I've deducted 14 percent off sales

[Nike]

Har dollar-kursen nogen betydning for udregningen af mile-stone?

[E_L]

@Bulder you are correct imo, it is the US, not Japan

[E_L]

you can always check in the press releases, they state all the approvals

[Bulder]

I have checked. Couldn't find anything on Japan. Not even a submission on Cassiopeia.

[E_L]

actually in the last press release the add MAIA for Japan, is that a mistake or did they forget to inform us on the approval? quote
:

[E_L]

link easier https://ir.genmab.com/news-releases/news-release-details/genmab-announces-european-marketing-authorization-darzalexr-2

[StockBull]

Vil ikke blive forbavset hvis Jan guider Dara royality 4.4-4.8 kr for 2020. For 2019 er mit bud 3.050 mia KR

[Bulder]

Can't find it. Only split dose for Japan.

[E_L]

@Nike yes, and not very positive in this case ; all european sales are converted into $ to calculate the total sales number for JNJ in $, on which the milestone is based. So a stronger $ means lower $ sales

[E_L]

Q3 saw a negative $ impact on dara sales of about 3% or 15mn ; that could just make the difference of making the milestone or not

[Bulder]

Now I see it:
in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant

[E_L]

Bulder , look under the header 'About DARZALEX....; and there the last paragraph starts with In Japan, DARZALEX intravenous infusion is approved for '....'